共 206 条
[1]
Sharifi N(2010)An update on androgen deprivation therapy for prostate cancer Endocrine-Related Cancer 17 R305-R315
[2]
Gulley JL(2004)Androgen deprivation therapy for prostate cancer: current status and future prospects Prostate 61 332-353
[3]
Dahut WL(2012)Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer Endocrine-related Cancer 19 R243-R253
[4]
Miyamoto H(2011)Small molecule inhibitors targeting the “achilles’ heel” of androgen receptor activity Cancer Res 71 1208-1213
[5]
Messing EM(2012)Increased survival with enzalutamide in prostate cancer after chemotherapy New England J Med 367 1187-1197
[6]
Chang C(2010)Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411-422
[7]
Shiota M(2010)Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 1147-1154
[8]
Yokomizo A(2011)Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 1995-2005
[9]
Naito S(2014)Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 424-433
[10]
Sadar MD(2013)Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 138-148